PSMA-positive circulating tumor cell detection and outcomes with abiraterone or enzalutamide treatment in men with metastatic castrate resistant prostate cancer.
Santosh GuptaSusan HalabiQian YangAkash RoyAlisa TubbsYamini GoreDaniel J GeorgeDavid M NanusEmmanuel S AntonarakisDaniel Costin DanilaRussell Zelig SzmulewitzRichard WenstrupAndrew J ArmstrongPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
We observed PSMA CTC heterogeneity between and within patients with mCRPC over time during abi/enza progression. CTC PSMA enumeration was adversely prognostic independent of clinical factors and disease burden. Further validation is warranted in the context of PSMA-targeted therapies.
Keyphrases
- pet ct
- circulating tumor
- circulating tumor cells
- prostate cancer
- pet imaging
- single cell
- cell free
- radical prostatectomy
- small cell lung cancer
- squamous cell carcinoma
- type diabetes
- stem cells
- computed tomography
- middle aged
- mesenchymal stem cells
- bone marrow
- loop mediated isothermal amplification
- metabolic syndrome